Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]
- Market Cap ₹ 111 Cr.
- Current Price ₹ 69.7
- High / Low ₹ 130 / 65.5
- Stock P/E
- Book Value ₹ 94.1
- Dividend Yield 0.00 %
- ROCE 8.05 %
- ROE 4.68 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.74 times its book value
Cons
- Company has low interest coverage ratio.
- Contingent liabilities of Rs.34.6 Cr.
- Debtor days have increased from 36.2 to 44.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 369 | 318 | 299 | |
| 351 | 282 | 276 | |
| Operating Profit | 17 | 36 | 23 |
| OPM % | 5% | 11% | 8% |
| 0 | 0 | 0 | |
| Interest | 14 | 15 | 15 |
| Depreciation | 15 | 17 | 17 |
| Profit before tax | -11 | 5 | -9 |
| Tax % | -18% | -41% | |
| -9 | 7 | -10 | |
| EPS in Rs | -5.73 | 4.25 | -6.16 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 174% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -14% |
| 3 Years: | -23% |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 16 | 16 |
| Reserves | 120 | 133 |
| 107 | 96 | |
| 91 | 121 | |
| Total Liabilities | 334 | 366 |
| 148 | 163 | |
| CWIP | 8 | 3 |
| Investments | 0 | 0 |
| 178 | 201 | |
| Total Assets | 334 | 366 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 4 | 43 | |
| -12 | -19 | |
| 5 | -22 | |
| Net Cash Flow | -3 | 1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 28 | 45 |
| Inventory Days | 185 | 303 |
| Days Payable | 99 | 199 |
| Cash Conversion Cycle | 113 | 149 |
| Working Capital Days | 11 | 5 |
| ROCE % | 8% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8h - Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 received from MUFG Intime India Private Limited (RTA) for the quarter ended 30th September, 2025.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 1 Oct
-
Announcement under Regulation 30 (LODR)-Change in Management
30 Sep - Ragini Chokshi & Co appointed secretarial auditors for FY2025-26 to FY2029-30.
-
Closure of Trading Window
30 Sep - Trading window closed Oct 1, 2025 until 48 hours after Sep 30, 2025 unaudited results.
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
29 Sep - 52nd AGM on Sep 29, 2025: adopted FY2024-25 financials, reappointed director, approved related-party transactions, appointed secretarial auditor.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from nse
Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations